EICHORPublic-registry site landscape for NCT07701941, “A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer”, a Hormone Receptor Positive study sponsored by Daiichi Sankyo. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07701941 (registry record) |
| Study title | A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer |
| Official title | A Phase 1b/2, Multicenter, Open-label, Dose Regimen Determination and Dose Expansion Trial to Evaluate the Safety, Tolerability, Anti-tumor Activity, and an Optimal Dose Regimen of Patritumab Deruxtecan (HER3-DXd) With Trastuzumab Deruxtecan (T-DXd) in Participants With Hormone Receptor Positive, HER2-low or HER2-ultralow, Unresectable or Metastatic Breast Cancer (HERTHENA-Breast02) |
| Sponsor | Daiichi Sankyo |
| Condition(s) | Hormone Receptor Positive; HER2-low or HER2-ultralow; Unresectable or Metastatic Breast Cancer |
| Phase | PHASE1 / PHASE2 |
| Listed sites | 0 |
| Intervention(s) | Patritumab deruxtecan, Trastuzumab deruxtecan |
Patient-friendly overview of this study: eichor.com/study/NCT07701941.
Eichor generates a preliminary site-risk snapshot for NCT07701941 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
